BIOMAT Database Logo BIOMAT Database Logo

A potent nonpeptide neuropeptide Y Y1 receptor antagonist, a benzodiazepine derivative. 1998

Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
Shionogi Research Laboratories, Shionogi and Co., Ltd., Osaka, Japan. shigeri@onri.go.jp

We describe here a nonpeptide neuropeptide Y Y1 receptor antagonist, 2,4-dioxo-1,5-bis(2-oxo-2-orthotolyl-ethyl)-3-[3-[3-([3-[3-(3-p iperidin-1-ylmethyl-phenoxy)-propylcarbamoyl]-propyl]-car bamoyloxymethyl)-phenyl]-ureido]-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diaz epine (Compound 1), which was previously synthesized as a linked type of dual cholecystokinin (CCK)-B and histamine H2 receptor antagonist. Compound 1 competitively inhibited [125I]peptide YY (PYY) binding to Y1 receptors in human neuroblastoma SK-N-MC cells with Ki of 6.4 +/- 1.0 nM, while it had no effect on [125I]PYY binding to Y2 or Y5 receptors even at 1 microM. Functionally, Compound 1 inhibited the Y1 receptor-mediated increase in cytosolic free Ca2+ concentration and Y1 receptor-mediated attenuation of cAMP accumulation in a dose-dependent manner with IC50 values of 95 +/- 5 and 320 +/- 10 nM in SK-N-MC cells, respectively. Neither its CCK-B receptor antagonistic moiety of Compound 1 (Compound 2) nor its histamine H2 receptor antagonistic moiety of Compound 1 (Compound 3) had any effect on [125I]PYY binding, suggesting that the entire structure of Compound 1 is essential for Y1 receptor blocking activity. It showed no significant activity (IC50 > 1 microM) in 30 receptor binding assays and 5 enzyme assays, with the exception of CCK-B and histamine H2 receptors. We conclude that Compound 1 is a useful molecule not only for studying the physiological role of neuropeptide Y but also for exploring more specific Y1 receptor antagonists.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D017476 Receptors, Neuropeptide Y Cell surface proteins that bind neuropeptide Y with high affinity and trigger intracellular changes which influence the behavior of cells. Neuropeptide Y Receptors,Neuropeptide Y Receptor,Receptor, Neuropeptide Y

Related Publications

Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
October 1995, The Journal of pharmacology and experimental therapeutics,
Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
Potent neuropeptide Y Y1 receptor antagonist, 1229U91: blockade of neuropeptide Y-induced and physiological food intake.
August 1996, Endocrinology,
Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226.
December 1994, European journal of pharmacology,
Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
August 1996, Molecular pharmacology,
Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide-preferring (NPY Y4) receptor.
January 1998, Peptides,
Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
Labeling of neuropeptide Y receptors in SK-N-MC cells using the novel, nonpeptide Y1 receptor-selective antagonist [3H]BIBP3226.
May 1995, European journal of pharmacology,
Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents.
October 1998, British journal of pharmacology,
Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist.
April 1995, FEBS letters,
Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
Neuropeptide Y Y1 receptor antagonist BIBP3226 produces conditioned place aversion in rats.
May 1999, Progress in neuro-psychopharmacology & biological psychiatry,
Y Shigeri, and M Ishikawa, and Y Ishihara, and M Fujimoto
1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists.
July 1999, Journal of medicinal chemistry,
Copied contents to your clipboard!